Accueil   Diary - News   All news Tollys closes Series A financing of €2.3 million

Tollys closes Series A financing of €2.3 million

 

 

Lyon, France, May 26, 2020 – Tollys, the developer of TL-532, the first synthetic specific agonist of Toll-like receptor 3 (“TLR3”) cancer immunotherapy, today announces the closing of a Series A round of financing totaling €2.3 million ($2.5M). This brings the total amount raised to €6.4M ($6.8M) since the company was founded in 2015. The round was closed on the basis of reaching the preclinical proof-of-concept of TL-532, supporting its development towards clinical trials.

 


Current shareholders and new private investors joined the round. The proceeds will be used to advance the preclinical development of TL-532. Notably, Tollys will use the proceeds to manufacture TL-532 and launch the regulatory safety studies required before entry into clinical trials in bladder cancer by late 2021/early 2022.

 

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree